Pages with the fewest revisions

Jump to: navigation, search

Showing below up to 50 results in range #1 to #50.

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)

  1. Mercaptopurine (Purinethol)‏‎ (1 revision - redirect page)
  2. ECOG performance status‏‎ (1 revision - redirect page)
  3. VTE‏‎ (1 revision - redirect page)
  4. BIDMC clinical trials‏‎ (1 revision - redirect page)
  5. Infigratinib (BGJ398)‏‎ (1 revision)
  6. T-cell acute lymphocytic leukemia‏‎ (1 revision - redirect page)
  7. Palifermin (Kepivance)‏‎ (1 revision)
  8. Neutral‏‎ (1 revision - redirect page)
  9. Aflibercept (Zaltrap)‏‎ (1 revision - redirect page)
  10. Fedratinib (Inrebic)‏‎ (1 revision)
  11. Diffuse large B-cell lymphoma - obsolete‏‎ (1 revision - redirect page)
  12. Stivarga‏‎ (1 revision - redirect page)
  13. Lusutrombopag (Mulpleta)‏‎ (1 revision)
  14. Ibritumomab (Zevalin)‏‎ (1 revision - redirect page)
  15. B-cell acute lymphoblastic leukaemia‏‎ (1 revision - redirect page)
  16. Tretinoin (Vesanoid)‏‎ (1 revision - redirect page)
  17. Haemophagocytic lymphohistiocytosis‏‎ (1 revision - redirect page)
  18. Glasdegib (Daurismo)‏‎ (1 revision)
  19. CC-292 (AVL-292)‏‎ (1 revision - redirect page)
  20. Carmustine (BiCNU)‏‎ (1 revision - redirect page)
  21. Mast cell diseases‏‎ (1 revision - redirect page)
  22. Anal carcinoma‏‎ (1 revision - redirect page)
  23. DVT‏‎ (1 revision - redirect page)
  24. Idelalisib (CAL-101)‏‎ (1 revision - redirect page)
  25. Argatroban‏‎ (1 revision - redirect page)
  26. Bevacizumab-bvzr (Zirabev)‏‎ (1 revision)
  27. Thiotepa (Tepadina)‏‎ (1 revision)
  28. Entrectinib (RXDX-101)‏‎ (1 revision - redirect page)
  29. Follicular lymphoma - obsolete‏‎ (1 revision - redirect page)
  30. Abiraterone‏‎ (1 revision - redirect page)
  31. Ponatinib (AP24534)‏‎ (1 revision - redirect page)
  32. Castleman’s disease‏‎ (1 revision - redirect page)
  33. Hematology/Oncology & allied organizations‏‎ (1 revision - redirect page)
  34. Inotuzumab ozogamicin (CMC-544)‏‎ (1 revision - redirect page)
  35. B-cell acute lymphoblastic leukaemia, Ph-positive‏‎ (1 revision - redirect page)
  36. NovoTTF-100A device (Optune)‏‎ (1 revision - redirect page)
  37. Acalabrutinib (ACP-196)‏‎ (1 revision - redirect page)
  38. HLH‏‎ (1 revision - redirect page)
  39. Dexamethasone‏‎ (1 revision - redirect page)
  40. SGN-CD19A‏‎ (1 revision - redirect page)
  41. Lomustine (Ceenu)‏‎ (1 revision - redirect page)
  42. Immune thrombocytopenia (ITP)‏‎ (1 revision - redirect page)
  43. Refametinib (BAY 869766)‏‎ (1 revision)
  44. Mycostatin (Nystatin)‏‎ (1 revision)
  45. Niraparib (MK4827)‏‎ (1 revision - redirect page)
  46. Inflammitant‏‎ (1 revision - redirect page)
  47. Allogeneic stem cells‏‎ (1 revision)
  48. Hodgkin lymphoma - obsolete‏‎ (1 revision - redirect page)
  49. Zytiga‏‎ (1 revision - redirect page)
  50. Cabozantinib (XL184)‏‎ (1 revision - redirect page)

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)